Print version | PDF version | Send article | RSS feed

Cerus Obtains Exclusive Rights to INTERCEPT Blood System from Baxter

15 Feb 2006 - Cerus Corporation and subsidiaries of Baxter International Inc. announced that they have entered into a definitive agreement for Cerus to obtain Baxter¡¦s remaining commercial rights to the INTERCEPT· Blood System for platelets and plasma effective February 1, 2006.
 
Cerus now has exclusive rights to the INTERCEPT Blood System for all three commonly transfused components: platelets, plasma and red blood cells, excluding rights in certain Asian countries for platelets and plasma.
 
Under the agreement Cerus has obtained exclusive commercial rights to market INTERCEPT Blood System for platelets and plasma worldwide, except in certain Asian countries in which rights have previously been granted to BioOne Corporation. Baxter will provide technical service, clinical education and select regulatory activities in Europe during the transition. Baxter will also continue manufacturing responsibilities in support of Cerus' development and commercialization activities for the platelet system and plasma system through 2008. Baxter will receive royalties based on future sales of INTERCEPT Blood System for platelets and plasma. These royalty provisions replace the previous agreement where Cerus received a sharing of gross profit from Baxter sales.
 
This restructuring does not affect the relationship with the companies' Asian partner, BioOne Corporation. BioOne continues to maintain the commercial rights to market and distribute INTERCEPT Blood System for platelets and plasma in Japan, China, Taiwan, South Korea, Thailand, Vietnam and Singapore, following receipt of regulatory approval in each of those countries.
 
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted diseases by inactivating certain pathogens that may be present in donated blood components.